No More Tears: The Dark Secrets of Johnson & Johnson by Gardiner Harris

Book Review 

Title: No More Tears: The Dark Secrets of Johnson & Johnson by Gardiner Harris 

Genre: Non-Fiction, Medical, History, Business 

Rating: 5 Stars 

There are few companies whose name has become as deeply embedded in everyday life as Johnson & Johnson. For generations, the company has been associated with babies, healthcare, medicine, bandages, and the reassuring promise that its products exist to make people’s lives safer and healthier. It is precisely this sense of trust that makes No More Tears: The Dark Secrets of Johnson & Johnson by Gardiner Harris such a disturbing, compelling, and ultimately essential work of investigative nonfiction. What Harris exposes is not simply a collection of isolated corporate scandals, but a deeply troubling history of decisions in which profit, reputation, and corporate power repeatedly came into conflict with patient safety and public accountability. Meticulously researched and written with the urgency of a thriller, No More Tears is an extraordinary piece of investigative journalism that deserves every one of its five stars. 

---

The origins of the book are particularly fascinating. Harris’s investigation was partly sparked by an unexpected conversation in 2004 with a Johnson & Johnson drug sales representative, whose account of unethical practices and their devastating consequences fundamentally changed the direction of his reporting. That initial encounter eventually developed into years of investigation into Johnson & Johnson and the wider pharmaceutical industry. Knowing this makes the book’s depth even more impressive. This is not an investigation assembled from a handful of recent controversies; it is the culmination of years of journalistic research and reporting. 

Perhaps the most powerful aspect of No More Tears is the contrast between Johnson & Johnson’s public image and the history Harris uncovers. The company built an extraordinary level of consumer trust, particularly through its association with children and families. Johnson’s Baby Powder became one of the most recognisable symbols of that image, making the controversies surrounding talc particularly devastating. Harris examines allegations and evidence surrounding asbestos contamination, the company’s response to concerns about the product, and the long-running legal battles that followed. The importance of this section is not simply the question of one product, but what the controversy reveals about the lengths a corporation may go to protect an enormously valuable brand. 

Harris’s investigation extends far beyond baby powder, however, and this is where the scale of the book becomes truly staggering. He examines Johnson & Johnson’s history with pharmaceuticals and medical devices, including Risperdal, Procrit, hip implants, opioids, and other products and practices that generated serious concerns about patient safety. Reviews of the book have highlighted Harris’s examination of the company’s marketing practices, regulatory failures, and controversies surrounding several of its products. Rather than treating these stories as unrelated scandals, Harris connects them to a broader question: what happens when an organisation powerful enough to influence medicine, regulators, doctors, and consumers becomes more concerned with protecting its interests than confronting the consequences of its decisions? 

That question is what elevates No More Tears above a conventional corporate exposé. Harris is interested not merely in what Johnson & Johnson allegedly did, but in the systems that allowed such behaviour to continue. The book therefore becomes an examination of corporate culture, government regulation, medical ethics, and the extraordinary imbalance of power between multinational healthcare companies and the people who depend upon their products. 

One of the book’s most unsettling subjects is the relationship between Johnson & Johnson and the U.S. Food and Drug Administration. Harris argues that regulatory structures repeatedly failed to provide adequate protection for consumers, while corporate influence could undermine effective oversight. The book’s criticism is not limited to Johnson & Johnson itself; it examines the wider ecosystem in which pharmaceutical companies, doctors, regulators, researchers, and politicians operate. This broader perspective is one of the book’s greatest strengths because it prevents the reader from simply dismissing the events as the actions of a few unethical executives. Harris instead asks much more uncomfortable questions about whether the system itself is capable of preventing similar abuses from happening again. 

The discussion of pharmaceutical marketing is particularly infuriating. The book explores the ways drugs were promoted to doctors and how commercial incentives could become intertwined with medical decision-making. The controversy surrounding Risperdal is especially disturbing, given the allegations concerning inappropriate marketing and the populations to whom the drug was promoted. These sections demonstrate how vulnerable patients can become when the commercial interests of a pharmaceutical company collide with the responsibility of healthcare professionals to put patient welfare first. 

The opioid crisis provides another devastating example. Johnson & Johnson’s role in the opioid epidemic, including the marketing of fentanyl products, demonstrates the enormous consequences that can follow when powerful companies aggressively pursue markets for potentially dangerous medicines. Harris places these events within the broader history of the opioid crisis rather than presenting them as an isolated corporate controversy. The result is a sobering examination of how pharmaceutical marketing can contribute to a public-health catastrophe whose consequences extend far beyond balance sheets and boardrooms. 

What makes the book particularly effective is Harris’s willingness to follow the consequences back to individual human beings. It would have been easy for a book covering such a large corporation to become dominated by financial figures, court cases, regulatory documents, and corporate correspondence. Although Harris provides plenty of evidence and documentation, he does not allow the people affected by these decisions to disappear beneath the statistics. The human consequences are what give the investigation its emotional force. 

This is also where the book becomes genuinely difficult to read. There are moments when the sheer accumulation of scandals becomes almost overwhelming. One horrifying revelation follows another, and the repetition creates a disturbing pattern: warnings appear; concerns are raised, evidence emerges, and yet commercial interests or institutional failures repeatedly interfere with meaningful action. The effect is cumulative. The reader is not simply shocked by one scandal; they become increasingly disturbed by the possibility that the same underlying problems can recur across completely different products and decades. 

Harris’s writing style is another major strength. Despite the enormous amount of research behind the book, he avoids making the narrative feel like a dry corporate history. His journalistic background is evident in the precision with which he constructs his arguments, but he also understands the importance of narrative momentum. Several reviewers have praised the book’s extensive research and its ability to transform complex corporate history into compelling investigative nonfiction. This balance between evidence and storytelling is crucial because No More Tears contains an enormous amount of information, yet it rarely feels as though the reader is simply being presented with a collection of documents. 

The book also benefits enormously from its willingness to challenge simplistic ideas about corporate morality. Johnson & Johnson is not portrayed merely as an inherently evil organisation in a cartoonish sense. Instead, Harris examines how corporate cultures develop, how employees can become invested in an organisation’s self-image, and how financial incentives can gradually distort ethical decision-making. This is arguably more frightening than a story about obviously malicious individuals because it suggests that catastrophic outcomes can emerge from systems in which everyone involved has a justification for what they are doing. 

The title itself becomes increasingly ironic as the book progresses. Johnson’s Baby Powder and the company’s family-friendly image evoke innocence, cleanliness, and parental trust. Harris places that image against decades of controversies involving pharmaceuticals, medical devices, marketing practices, regulatory failures, and alleged corporate misconduct. The contrast is devastating. The further the reader progresses, the more difficult it becomes to separate the comforting brand from the much darker corporate history underneath it. 

If I had one criticism, it would be that the sheer volume of material can occasionally make the book feel overwhelming. Harris covers an enormous number of people, products, lawsuits, scientific studies, regulatory decisions, and corporate developments. Readers who are unfamiliar with the pharmaceutical industry may occasionally find themselves having to pause and absorb the information before continuing. Some sections are also more immediately gripping than others. Nevertheless, I would argue that this density is ultimately a consequence of the book’s ambition rather than a fundamental weakness. Harris is attempting to demonstrate a pattern across decades, and doing so necessarily requires an enormous amount of evidence. 

The book’s greatest achievement is therefore not simply exposing Johnson & Johnson’s controversies. It is forcing readers to reconsider what trust means in healthcare. Consumers routinely assume that products sold by enormous pharmaceutical companies have passed through rigorous systems of testing and oversight. Doctors and patients depend upon scientific information being presented honestly. Regulators are expected to protect the public. No More Tears examines what happens when those assumptions fail. 

It also leaves readers with an uncomfortable question about accountability. Financial settlements and corporate fines may provide some compensation, but they do not necessarily undo the damage caused to patients and families. Nor do they automatically prevent similar behaviour from occurring again. Harris’s investigation consequently feels less like a story about the past and more like a warning about the present and future. 

Ultimately, No More Tears is an outstanding example of investigative nonfiction. Gardiner Harris has taken a company that many readers probably associate with childhood, family, and healthcare and subjected it to an extraordinarily thorough examination. The result is shocking, infuriating, fascinating, and deeply thought-provoking. The book succeeds because it combines meticulous reporting with a powerful narrative about trust, money, medicine, regulation, and the human cost of corporate decisions. 

Five stars feels entirely justified. No More Tears is not an easy book, nor is it particularly comforting, but it is precisely the kind of investigative journalism that nonfiction should provide research that challenges assumptions, exposes uncomfortable truths, gives a voice to people affected by powerful institutions, and leaves the reader looking at an ordinary household name in an entirely different way. For anyone interested in corporate scandals, pharmaceutical history, medical ethics, investigative journalism, or the complicated relationship between business and public health, this is an essential read. Harris has produced a devastating examination of how an organisation built on trust can become consumed by the need to protect it, and what can happen when protecting the reputation of a company becomes more important than protecting the people who trusted it. 

Buy it here: 

Paperback/Hardcover: amazon.co.uk                            amazon.com  

Kindle Edition: amazon.co.uk                                   amazon.com